185 related articles for article (PubMed ID: 24186137)
1. High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases.
Jang S; Chun SM; Hong SM; Sung CO; Park H; Kang HJ; Kim KP; Lee YJ; Yu E
Mod Pathol; 2014 May; 27(5):731-9. PubMed ID: 24186137
[TBL] [Abstract][Full Text] [Related]
2. GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct.
Sasaki M; Matsubara T; Nitta T; Sato Y; Nakanuma Y
PLoS One; 2013; 8(12):e81706. PubMed ID: 24312577
[TBL] [Abstract][Full Text] [Related]
3. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas.
Hsu M; Sasaki M; Igarashi S; Sato Y; Nakanuma Y
Cancer; 2013 May; 119(9):1669-74. PubMed ID: 23335286
[TBL] [Abstract][Full Text] [Related]
4. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.
Schlitter AM; Born D; Bettstetter M; Specht K; Kim-Fuchs C; Riener MO; Jeliazkova P; Sipos B; Siveke JT; Terris B; Zen Y; Schuster T; Höfler H; Perren A; Klöppel G; Esposito I
Mod Pathol; 2014 Jan; 27(1):73-86. PubMed ID: 23828315
[TBL] [Abstract][Full Text] [Related]
5. Different carcinogenic process in cholangiocarcinoma cases epidemically developing among workers of a printing company in Japan.
Sato Y; Kubo S; Takemura S; Sugawara Y; Tanaka S; Fujikawa M; Arimoto A; Harada K; Sasaki M; Nakanuma Y
Int J Clin Exp Pathol; 2014; 7(8):4745-54. PubMed ID: 25197345
[TBL] [Abstract][Full Text] [Related]
6. GNAS Is frequently mutated in a specific subgroup of intraductal papillary neoplasms of the bile duct.
Tsai JH; Yuan RH; Chen YL; Liau JY; Jeng YM
Am J Surg Pathol; 2013 Dec; 37(12):1862-70. PubMed ID: 24061513
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.
Voss JS; Holtegaard LM; Kerr SE; Fritcher EG; Roberts LR; Gores GJ; Zhang J; Highsmith WE; Halling KC; Kipp BR
Hum Pathol; 2013 Jul; 44(7):1216-22. PubMed ID: 23391413
[TBL] [Abstract][Full Text] [Related]
8. GNAS codon 201 mutations are uncommon in intraductal papillary neoplasms of the bile duct.
Matthaei H; Wu J; Dal Molin M; Debeljak M; Lingohr P; Katabi N; Klimstra DS; Adsay NV; Eshleman JR; Schulick RD; Kinzler KW; Vogelstein B; Hruban RH; Maitra A
HPB (Oxford); 2012 Oct; 14(10):677-83. PubMed ID: 22954004
[TBL] [Abstract][Full Text] [Related]
9. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
Andersen JB; Spee B; Blechacz BR; Avital I; Komuta M; Barbour A; Conner EA; Gillen MC; Roskams T; Roberts LR; Factor VM; Thorgeirsson SS
Gastroenterology; 2012 Apr; 142(4):1021-1031.e15. PubMed ID: 22178589
[TBL] [Abstract][Full Text] [Related]
10. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features.
Liau JY; Tsai JH; Yuan RH; Chang CN; Lee HJ; Jeng YM
Mod Pathol; 2014 Aug; 27(8):1163-73. PubMed ID: 24406866
[TBL] [Abstract][Full Text] [Related]
11. Frequent GNAS and KRAS mutations in pyloric gland adenoma of the stomach and duodenum.
Matsubara A; Sekine S; Kushima R; Ogawa R; Taniguchi H; Tsuda H; Kanai Y
J Pathol; 2013 Mar; 229(4):579-87. PubMed ID: 23208952
[TBL] [Abstract][Full Text] [Related]
12. The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome.
Robertson S; Hyder O; Dodson R; Nayar SK; Poling J; Beierl K; Eshleman JR; Lin MT; Pawlik TM; Anders RA
Hum Pathol; 2013 Dec; 44(12):2768-73. PubMed ID: 24139215
[TBL] [Abstract][Full Text] [Related]
13. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.
Simbolo M; Fassan M; Ruzzenente A; Mafficini A; Wood LD; Corbo V; Melisi D; Malleo G; Vicentini C; Malpeli G; Antonello D; Sperandio N; Capelli P; Tomezzoli A; Iacono C; Lawlor RT; Bassi C; Hruban RH; Guglielmi A; Tortora G; de Braud F; Scarpa A
Oncotarget; 2014 May; 5(9):2839-52. PubMed ID: 24867389
[TBL] [Abstract][Full Text] [Related]
14. KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients.
Xu RF; Sun JP; Zhang SR; Zhu GS; Li LB; Liao YL; Xie JM; Liao WJ
Biomed Pharmacother; 2011 Feb; 65(1):22-6. PubMed ID: 21051183
[TBL] [Abstract][Full Text] [Related]
15. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma.
Goeppert B; Frauenschuh L; Renner M; Roessler S; Stenzinger A; Klauschen F; Warth A; Vogel MN; Mehrabi A; Hafezi M; Boehmer K; von Deimling A; Schirmacher P; Weichert W; Capper D
Mod Pathol; 2014 Jul; 27(7):1028-34. PubMed ID: 24309328
[TBL] [Abstract][Full Text] [Related]
16. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
[TBL] [Abstract][Full Text] [Related]
17. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
Shen Y; Wang J; Han X; Yang H; Wang S; Lin D; Shi Y
PLoS One; 2013; 8(12):e81628. PubMed ID: 24339949
[TBL] [Abstract][Full Text] [Related]
18. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Borger DR; Tanabe KK; Fan KC; Lopez HU; Fantin VR; Straley KS; Schenkein DP; Hezel AF; Ancukiewicz M; Liebman HM; Kwak EL; Clark JW; Ryan DP; Deshpande V; Dias-Santagata D; Ellisen LW; Zhu AX; Iafrate AJ
Oncologist; 2012; 17(1):72-9. PubMed ID: 22180306
[TBL] [Abstract][Full Text] [Related]
19. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.
Ross JS; Wang K; Gay L; Al-Rohil R; Rand JV; Jones DM; Lee HJ; Sheehan CE; Otto GA; Palmer G; Yelensky R; Lipson D; Morosini D; Hawryluk M; Catenacci DV; Miller VA; Churi C; Ali S; Stephens PJ
Oncologist; 2014 Mar; 19(3):235-42. PubMed ID: 24563076
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas.
Della Torre G; Pasquini G; Pilotti S; Alasio L; Civelli E; Cozzi G; Milella M; Salvetti M; Pierotti MA; Severini A
Diagn Mol Pathol; 2000 Mar; 9(1):41-6. PubMed ID: 10718212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
